Interestingly, we found that a significantly higher proportion of PRAME overexpressing cancer cells express immune checkpoint ligands such as PD‐L1, CD86, GAL‐9 and VISTA, which may in part explain the reduced T cell mediated activation and killing of PRAME overexpressing cancer cells. The gene discussed is CD86; the disease is cancer.